How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Recursion Pharmaceuticals ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. If you are trying to figure out whether Recursion Pharmaceuticals is ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

AI development is often framed as a race among countries, companies and academic researchers. But figuring out who’s actually ...

Access detailed historical stock prices, including daily closing prices, for RXRX. Analyze past performance trends, track price movements, and explore historical data to inform your investment ...

An agent can produce a mathematically elegant, third-normal-form schema that is functionally irrelevant because it fails to capture the political or operational nuances of the organization. Deploying ...